Feedback from the field is incredibly important when participating in new payment models like the Oncology Care Model, said Basit Chaudhry, MD, PhD, founder of Tuple Health.
Feedback from the field is incredibly important when participating in new payment models like the Oncology Care Model, said Basit Chaudhry, MD, PhD, founder of Tuple Health.
Transcript
With Oncology Care First being delayed at least a year now, where do you see opportunities for CMS to make some changes to the model based on the ongoing challenges practices have reported in the Oncology Care Model?
One of the things that Medicare talks about quite a bit in these payment models, particularly through CMMI [Center for Medicare and Medicaid Innovation], is that they're learning models. And I think that's the very much the right spirit. You know, these kinds of changes are so complicated, even for an entity as large as Medicare, there's no way to get it right in the beginning. So, this whole tact of making things a learning approach, I think, is really critical. And I think it's very, very important to really think, from the payer perspective, really think carefully about what did work, what did not, and I know Medicare tries to do this, and then really implement those changes. And I think one of the big things that we've seen particularly for a model as complicated as OCM, is, I think, until you're actually living it and doing it directly, it's hard to know what it's like.
So, what we really hope is that feedback from the field is one of the drivers for change and OCF in the design. So, I think taking a human-centric or user-centered design approach towards the problem would be something I'd very much recommend and hope that we see payers do more and more.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More